BMC Med. 2022;20(1):181.

Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection.

, , , , , , , , , , , , , , ,

제1저자 강창경, 신현무, 최평균 · 교신저자 박완범, 이창한, 서준영

PMID 35508998 PMC9067342 DOI 10.1186/s12916-022-02383-4 IF 8.7 감염내과

소속 (14)

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, 03080, South Korea.
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, South Korea.
BK21 FOUR Biomedical Science Project, Seoul National University College of Medicine, Seoul, 03080, South Korea.
Wide River Institute of Immunology, Seoul National University, Hongcheon, 25159, South Korea.
Department of Pharmacology, Seoul National University College of Medicine, Seoul, 03080, South Korea.
Severance Biomedical Science Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, 03722, South Korea.
Department of Internal Medicine, Seoul Asan Medical Center, Seoul, 05505, South Korea.
Department of Anatomy & Cell Biology, Seoul National University College of Medicine, Seoul, 03080, South Korea.
Medical Research Institute, Seoul National University College of Medicine, Seoul, 08030, South Korea.
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, South Korea. chlee-antibody@snu.ac.kr.
BK21 FOUR Biomedical Science Project, Seoul National University College of Medicine, Seoul, 03080, South Korea. chlee-antibody@snu.ac.kr.
Department of Pharmacology, Seoul National University College of Medicine, Seoul, 03080, South Korea. chlee-antibody@snu.ac.kr.
Severance Biomedical Science Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, 03722, South Korea. jyseo0724@yuhs.ac.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, 03080, South Korea. wbpark1@snu.ac.kr.

Abstract

BACKGROUND Practical guidance is needed regarding the vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals in resource-limited countries. It includes the number of vaccine doses that should be given to unvaccinated patients who experienced COVID-19 early in the pandemic.

METHODS We recruited COVID-19 convalescent individuals who received one or two doses of an mRNA vaccine within 6 or around 18 months after a diagnosis of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. Their samples were assessed for IgG-binding or neutralizing activity and cell-mediated immune responses against SARS-CoV-2 wild-type and variants of concern.

RESULTS A total of 43 COVID-19 convalescent individuals were analyzed in the present study. The results showed that humoral and cellular immune responses against SARS-CoV-2 wild-type and variants of concern, including the Omicron variant, were comparable among patients vaccinated within 6 versus around 18 months. A second dose of vaccine did not significantly increase immune responses.

CONCLUSION One dose of mRNA vaccine should be considered sufficient to elicit a broad immune response even around 18 months after a COVID-19 diagnosis.

Keywords

COVID-19Immune responseSARS-CoV-2VaccinationmRNA

Figures

**Fig. 1** Humoral responses against different strains of SARS-CoV-2 according to vaccination timing and doses after mild COVID-19. a IgG-binding activities measured using an enzyme-linked immunosorbent assay. b Neutralizing activities measured using a live virus neutralization test. c Neutralizing activities based on a pseudovirus neutralization test. Horizontal lines in a denote binding activity values from the negative control specimen. *P < 0.05, **P < 0.005 NS, not significant; FRNT, focus reduction neutralization test; AUC, area under the curve

**Fig. 2** T cell-mediated immune responses against wild-type and Delta variant SARS-CoV-2 according to vaccination timing after COVID-19. a Activation-induced marker⁺ (AIM⁺) T cells stimulated by wild-type whole spike protein. b, c AIM⁺ CD4⁺b and CD8⁺c T cells stimulated by matched wild-type and Delta variant spike peptide pools. *P < 0.05, **P < 0.005 NS, not significant

그림 출처: PubMed Central 공개 논문 (PMC9067342)

Conflict of interest statement

The authors declare that they have no competing interests.

그 밖의 정보